A
Description
Norwegian clinical-stage pharmaceutical company founded in 2006, based on research from FMC BioPolymer and the Norwegian University of Science and Technology. Develops alginate oligosaccharide technology for improved drug delivery and treatment of cystic fibrosis, COPD and antibiotic-resistant infections. Received 46M+ USD in non-dilutive funding. 17 patent families. Based in Sandvika, Norway.